Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2022 Jan 10:12:825100.
doi: 10.3389/fendo.2021.825100. eCollection 2021.

Commentary: Mortality Risk of Antidiabetic Agents for Type 2 Diabetes With COVID-19: A Systematic Review and Meta-Analysis

Li-Min Zhao  1 , Xie-Hui Chen  1 , Mei Qiu  2
Affiliations
Comment

Commentary: Mortality Risk of Antidiabetic Agents for Type 2 Diabetes With COVID-19: A Systematic Review and Meta-Analysis

Li-Min Zhao et al. Front Endocrinol (Lausanne). .
No abstract available

Keywords: COVID- 19; DPP4 (dipeptidyl peptidase 4) inhibitors; SGLT2I; death; glp1 agonists; type 2 diabetes mellitus.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
Forest plots illustrating the association of DPP4i (Figure 1.1), SGLT2i (Figure 1.2), and GLP1RA (Figure 1.3) use with COVID-19 mortality risk in T2DM patients. DPP4i, dipeptidyl peptidase-4 inhibitors; SGLT2i, sodium-glucose cotransporter-2 inhibitors; GLP1RA, glucagon-like peptide-1 receptor agonists; T2DM, type 2 diabetes mellitus; CI, confidence interval.
See this image and copyright information in PMC

Comment on

References

    1. Kan C, Zhang Y, Han F, Xu Q, Ye T, Hou N, et al. . Mortality Risk of Antidiabetic Agents for Type 2 Diabetes With COVID-19: A Systematic Review and Meta-Analysis. Front Endocrinol (Lausanne) (2021) 12:708494. doi: 10.3389/fendo.2021.708494 - DOI - PMC - PubMed
    1. Ramos-Rincón JM, Pérez-Belmonte LM, Carrasco-Sánchez FJ, Jansen-Chaparro S, De-Sousa-Baena M, Bueno-Fonseca J, et al. . Cardiometabolic Therapy and Mortality in Very Old Patients With Diabetes Hospitalized Due to COVID-19. J Gerontol A Biol Sci Med Sci (2021) 76(8):e102–9. doi: 10.1093/gerona/glab124 - DOI - PMC - PubMed
    1. Khunti K, Knighton P, Zaccardi F, Bakhai C, Barron E, Holman N, et al. . Prescription of Glucose-Lowering Therapies and Risk of COVID-19 Mortality in People With Type 2 Diabetes: A Nationwide Observational Study in England. Lancet Diabetes Endocrinol (2021) 9(5):293–303. doi: 10.1016/S2213-8587(21)00050-4 - DOI - PMC - PubMed
    1. Elibol A, Eren D, Erdoğan MD, Elmaağaç M, Dizdar OS, Çelik O, et al. . Factors Influencing on Development of COVID-19 Pneumonia and Association With Oral Anti-Diabetic Drugs in Hospitalized Patients With Diabetes Mellitus. Prim Care Diabetes (2021) 15(5):806–12. doi: 10.1016/j.pcd.2021.08.001 - DOI - PMC - PubMed
    1. Israelsen SB, Pottegård A, Sandholdt H, Madsbad S, Thomsen RW, Benfield T. Comparable COVID-19 Outcomes With Current Use of GLP-1 Receptor Agonists, DPP-4 Inhibitors or SGLT-2 Inhibitors Among Patients With Diabetes Who Tested Positive for SARS-CoV-2. Diabetes Obes Metab (2021) 23(6):1397–401. doi: 10.1111/dom.14329 - DOI - PMC - PubMed

MeSH terms

Substances